Today: 20 March 2026
Browse Category

NASDAQ:CIEN 29 December 2025 - 5 March 2026

Corning stock slides after Broadcom warns AI racks will stick with copper longer

Corning stock slides after Broadcom warns AI racks will stick with copper longer

Corning shares dropped 4.4% Thursday after Broadcom CEO Hock Tan said customers will stick with copper, not optical links, inside AI racks for now. Corning CFO Ed Schlesinger warned of a slower “scale-up” for AI networking, pointing to a possible inflection closer to 2028. Broadcom stock rose 5.3%, while Ciena fell 15.2%. Analysts see co-packaged optics adoption delayed by at least two years.
Ciena stock jumps about 6% as tech rebounds; CIEN traders eye March catalyst

Ciena stock jumps about 6% as tech rebounds; CIEN traders eye March catalyst

Ciena Corp shares rose about 6% to $267.26 by early afternoon Monday after an earlier drop, rebounding alongside other networking stocks like Corning and Nokia. The move followed analyst upgrades and news of new fiber projects in the Balkans. Wall Street’s tech sector gains came as metals prices fell sharply. Investors are watching for updates at the Mobile World Congress in early March.
2 February 2026
Ciena stock tumbles 14% as AI-networking names retreat — what investors watch next

Ciena stock tumbles 14% as AI-networking names retreat — what investors watch next

Ciena shares fell 14% to $222.73 Thursday after an early spike to $260, with about 2.8 million shares traded by early afternoon. Lumentum dropped 11% and Coherent 9% as tech stocks slid ahead of Friday’s U.S. jobs report. CEO Gary Smith sold 83,552 shares on Jan. 5 at an average $229.44. Ciena will present at the Needham Growth Conference on Jan. 13.
Lumentum stock slides 8% as optics peers stumble; investors eye February earnings update

Lumentum stock slides 8% as optics peers stumble; investors eye February earnings update

Lumentum Holdings shares dropped 7.6% to $356.69 Monday afternoon, leading declines among optical networking stocks as Coherent, Ciena, and Applied Optoelectronics also fell. The selloff followed a sharp rally that brought Lumentum near its December peak, with trading volume at 4.9 million shares by 3:24 p.m. EST. Investors are watching upcoming earnings and industry events for signs of continued AI-driven demand.
Lumentum stock rises 4% as AI data‑center optics rally kicks off 2026

Lumentum stock rises 4% as AI data‑center optics rally kicks off 2026

Lumentum shares climbed 4.3% to $384.31 Friday afternoon, outperforming the broader market as optical and AI hardware stocks rallied. The stock traded between $374.87 and $391.92 during the session. Sector peers Coherent and Ciena also posted gains. Traders are watching for upcoming U.S. jobs and inflation data next week.
AAOI stock jumps 13% today as AI optics names rally and short interest stays high

AAOI stock jumps 13% today as AI optics names rally and short interest stays high

Applied Optoelectronics shares jumped 13% to $39.55 in midday trading Friday, following a previous close of $34.86. Short interest stands at 12.7 million shares, about one-fifth of the float, raising short squeeze risk. The company last forecast Q4 revenue of $125 million to $140 million and reported its first major 800G transceiver order in December. Next earnings are expected Feb. 25.
Lumentum stock tumbles as year-end tech pullback hits AI optics names

Lumentum stock tumbles as year-end tech pullback hits AI optics names

Lumentum Holdings shares fell 4.1% to $374.87 by midday Monday, outpacing declines in tech benchmarks and optical peers. The stock swung between $390 and $364.50, retreating from last week’s 52-week high. Coherent and Ciena also dropped, but by less than Lumentum. Investors trimmed exposure to AI-linked names ahead of the New Year, with trading volumes thin and markets watching Fed minutes and jobless claims.

Stock Market Today

  • Regeneus Ltd (RGS.AX) Jumps 33% on Heavy Volume, Signals Short-Term Upside
    March 19, 2026, 10:42 PM EDT. Regeneus Ltd (RGS.AX) surged 33.33% to A$0.012 on March 20, 2026, driven by unusually heavy volume of 4.28 million shares, nearly seven times the average. The stock broke above its 50-day and 200-day moving averages, indicating increased short-term trader interest in this clinical-stage biotech focused on osteoarthritis and wound healing. Despite negative earnings per share and liquidity constraints, the price action reflects momentum trading in a volatile sector. Traders should watch intraday support at A$0.010 and resistance near the year high of A$0.020. With a Meyka AI rating of 64.90 (Grade B), the stock is rated HOLD amid high volatility and thin order books typical of small-cap biotechs on the Australian Securities Exchange (ASX).
Go toTop